Medicamen Organics Ltd.

24.05-0.5 (-2.04%)

26 Oct, 12:00 AM

Income Statement

Abridged

Understanding Income Statement

Medicamen Organics Ltd. income statement covering revenue, operating profit, EBITDA, PAT and EPS across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2021 Mar 31	2022 Mar 31	2023 Mar 31	R 2024 Mar 31	2025 Mar 31	2026 Mar 31
	2021 Mar 31	2022 Mar 31	2023 Mar 31	R 2024 Mar 31	2025 Mar 31	2026 Mar 31
Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR
Total Revenue	25.05	20.98	22.15	25.27	38.19	22.63
Cost of Operating Revenue	17.56	14.93	15.00	15.32	23.92	18.45
Gross Profit	7.49	6.05	7.15	9.95	14.27	4.18
Gross Margin	29.9	28.8	32.3	39.4	37.4	18.5
Total Operating Expenses	23.98	20.46	21.03	21.25	32.34	27.28
Operating Profit	1.07	0.51	1.12	4.02	5.85	-4.65
Operating Margin	4.3	2.4	5.0	15.9	15.3	-20.5
Financing Income/(Expense) - Net	-0.43	-0.41	-0.55	-0.63	-0.42	-0.68
Profit before Taxes	0.39	0.13	1.28	4.44	5.43	-5.28
Income Taxes	0.15	0.05	0.03	1.81	1.38	-1.26
Profit after Tax	0.24	0.08	1.25	2.62	4.05	-4.02
PAT Margin	1.0	0.4	5.7	10.4	10.6	-17.8
EPS - Basic - ex Extraordinary Items	0.21	0.07	1.07	3.47	3.66	-3.41
EPS - Diluted - ex Extraordinary Items	0.21	0.07	1.07	3.47	3.66	-3.41
EBIT	1.07	0.51	1.12	4.02	5.85	-4.65
EBITDA	1.86	1.32	1.92	4.74	6.59	-3.75
EBITDA Margin	7.4	6.3	8.7	18.7	17.2	-16.6

Balance Sheet

Abridged

Understanding Balance Sheet

Medicamen Organics Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2021 Mar 31	2022 Mar 31	2023 Mar 31	R 2024 Mar 31	2025 Mar 31	2026 Mar 31
	2021 Mar 31	2022 Mar 31	2023 Mar 31	R 2024 Mar 31	2025 Mar 31	2026 Mar 31
Source:	AR	AR	AR	AR	AR	AR
Total Current Assets	14.86	15.56	20.62	27.31	45.43	36.86
Long-Term Investments	-	-	-	0.02	0.02	0.05
Property Plant & Equipment - Net	10.51	10.32	9.81	10.49	12.33	12.93
Total Non-Current Assets	10.66	10.56	10.06	11.13	13.78	14.77
Total Assets	25.52	26.12	30.68	38.44	59.21	51.63
Total Current Liabilities	16.54	17.13	20.89	21.62	27.16	21.75
Long Term Debt	1.15	0.98	0.55	0.16	0.16	1.04
Total Non-Current Liabilities	1.62	1.52	1.10	1.56	1.57	1.29
Total Liabilities	18.16	18.65	21.99	23.18	28.73	23.04
Total Shareholders' Equity	7.36	7.47	8.69	15.26	30.13	28.73
Minority Interest	-	-	-	-	0.35	-0.14
Total Equity	7.36	7.47	8.69	15.26	30.48	28.59
Total Liabilities & Equity	25.52	26.12	30.68	38.44	59.21	51.63

Cash Flow

Abridged

Understanding Cash Flow Statement

Medicamen Organics Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2021 Mar 31	2022 Mar 31	2023 Mar 31	R 2024 Mar 31	2025 Mar 31	2026 Mar 31
	2021 Mar 31	2022 Mar 31	2023 Mar 31	R 2024 Mar 31	2025 Mar 31	2026 Mar 31
Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR
Operating CF bef Changes in Working Cap	1.52	1.38	2.59	4.57	5.93	-4.78
Working Capital - Increase/(Decrease)	-2.75	-1.45	-3.19	-8.22	-10.90	-0.50
Net CF from Operating Activities	-1.23	-0.07	-0.60	-3.65	-4.96	-5.28
Capital Expenditures - Net	-0.04	0.62	0.29	0.35	2.45	1.74
Net CF from Investing Activities	0.04	-0.62	-0.29	-0.35	-2.45	-1.74
Stock - Issuance/(Retirement) - Net	-	-	-	2.60	3.10	0.47
Debt - LT & ST - Issuance/(Retirement) - Total	1.73	0.66	1.55	0.86	-0.30	1.94
Net Cash Flow from Financing Activities	1.29	0.23	1.00	4.01	10.99	4.19
Free Cash Flow to Equity	0.54	-0.03	0.67	-3.14	-7.71	-5.08
Free Operating CF net dividend	-	-0.69	-0.89	-4.00	-7.41	-7.02
Free Operating CF	-	-0.69	-0.89	-4.00	-7.41	-7.02

Business Segment Analysis

FY End:

Mar 26

Medicamen Organics Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Pharmaceuticals (100.0%)₹ 1.74 Cr

Revenue / Sales

Pharmaceuticals (100.0%)₹ 22.63 Cr

Assets

Pharmaceuticals (100.0%)₹ 51.63 Cr

Operating Income

Pharmaceuticals (100.0%)₹ -4.65 Cr

Regional Segment Analysis

Medicamen Organics Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

We don't have enough data to show regional segment analysis for Medicamen Organics Ltd.

Historical Segment Analysis

Track how Medicamen Organics Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Pharmaceuticals	1	0	0	2	2

Frequently Asked Questions

What is the revenue of Medicamen Organics Ltd.?

The latest trailing twelve month revenue of Medicamen Organics Ltd. is ₹ 22.63 Cr, reflecting a 1-year growth of -40.74% and a 3-year CAGR of 0.72%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Medicamen Organics Ltd.?

The latest trailing twelve month net profit (PAT) of Medicamen Organics Ltd. is ₹ -4.02 Cr, with a 3-year earnings CAGR of -73.08%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Medicamen Organics Ltd.?

The trailing twelve month EBITDA of Medicamen Organics Ltd. is approximately ₹ -4.65 Cr (based on an operating margin of -20.54%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Medicamen Organics Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Medicamen Organics Ltd. is -3.41. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Medicamen Organics Ltd.?

The debt-to-equity ratio of Medicamen Organics Ltd. stands at 0.50. The interest coverage ratio is -6.55x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Medicamen Organics Ltd.?

The estimated book value per share of Medicamen Organics Ltd. is 19.31 (derived from a P/B ratio of 1.25 and market price of ₹ 24.05), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Medicamen Organics Ltd.?

The trailing twelve month operating cash flow of Medicamen Organics Ltd. is ₹ -5.28 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Medicamen Organics Ltd. report consolidated or standalone financials?

Medicamen Organics Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.